The coronavirus pandemic caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide, infecting more than 23.3 million people and killing more than 807,000 people. Knowledge shows that peak cases occur in the elderly, those with weakened immune systems, and those with underlying medical conditions, such as high blood pressure, diabetes, kidney disease, central disorders, and lung disease, among others.
Previous studies have also linked high blood pressure to severe coronavirus disease (COVID-19). Now, a new examination by researchers at norwich School of Medicine at the University of East Anglia has found that the threat of severe COVID-19 and death is reduced in patients with high blood pressure taking angiotensin conversion enzyme (ACE) inhibitors or angiotensin. Receptors. Blockers (ARB).
Renin-angiotensin-aldosterone system inhibitors (RAAS), which come with ECAi and ARB, are an elegance to medications used to treat high blood pressure.
At the start of the pandemic, studies in the most affected countries such as China and Italy showed that morbidity and mortality rates were higher in patients with a medical history of hypertension, diabetes, chronic kidney disease, coronary heart disease and obesity.
SARS-CoV-2 infects human cells to the angiotensin conversion enzyme (ACE2) receptor, which serves as the gateway for the virus to penetrate and invade healthy cells. ACE2, the SARS-CoV-2 binding site, is an essential component of the renin-angiotensin-aldosterone system (RAAS) counterregulation pathway, which is one of the highest vital regulators of blood pressure, inflammation and fibrosis. Array is also essential for pathophysiology of high blood pressure, central disease and kidney disease.
The role of RAAS inhibitors, namely IECA and ARB, in the coronavirus pandemic has not been evaluated very well. With cases on the rise worldwide, it is imperative to better perceive the effect of these medicines in inflamed hypertensive patients with COVID-19.
In this study, published in the journal Current Atherosclerosis Reports, the study team noted that high blood pressure medications improve COVID-19 survival rates in others with high blood pressure. The new findings contradict previous studies that suggest that antihypertensives would possibly worsen coronavirus infection.
To reach the effects of the study, the study team tested the effect of taking non-unusual medications in coronavirus patients with medical conditions. They conducted a meta-analysis using resources such as PubMed, Embase and the pre-printed medRxiv knowledge base, looking for knowledge about patients taking antihypertensives with COVID-19.
The team included 19 studies similar to the drugs COVID-19 and ACEi and ARB, which affected more than 28,000 patients. The researchers’ knowledge of COVID-19 patients who take their antihypertensives with those who do not, focusing on the fact that patients had experienced critical events, such as admission to intensive care and undergoing invasive or noninvasive ventilation, and death. .
Patients with high blood pressure who continued to take antihypertensives were 0.67 times less likely to have a critical or fatal end result than those who were not, the researchers concluded. However, for those who take the same medications for other situations such as kidney and central failure, stroke and diabetes, their final results for COVID-19 were neither worse nor better.
“We found that one-third of Covid-19 patients with upper blood pressure and a quarter of patients generally took IECA/ARA. This is due to the increased threat of infection in patients with comorities such as cardiovascular disease, hypertension and diabetes,” Dr Vassilios Vassiliou of the EEU School of Medicine said in a statement.
“But the vital thing we’ve shown is that there’s no evidence that these drugs can increase the severity of Covid-19 or the death threat,” he added.
Dr. Vassiliou added that the study team found that the death threat and critical results were minor. As a result, medications to patients with high blood pressure.
“This is the largest meta-analysis that adds critical occasions and mortality knowledge in patients prescribed with IECA/ARB and discovered evidence of the effects of chronic use of IECA/ARB, especially in the hypertensive cohort with COVID-19,” the researchers concluded.
“As such, we strongly encouraged patients to follow the TREATMENT with RAAS inhibitor drugs of the COVID-19 pandemic,” they added.
Written by
Angela is a career and heart nurse. He graduated by far (Cum Laude) from his Bachelor of Nursing from the University of Baguio, Philippines. Lately she is completing her master’s degree where she specialized in maternal and child nursing and has worked as a clinical instructor and educator at the School of Nursing at the University of Baguio.
Use one of the following to cite this article in your essay, job, or report:
Apa
Laguipus, Angela. (2020, 24 August). Survival rates of antihypertensives in COVID-19. News-Medical. Retrieved 24 August 2020 in https://www.news-medical.net/news/20200824/Antihypertensives–COVID-19-survival-rates.aspx.
Mla
Laguipus, Angela. “COVID-19 antihypertensive survival rates”. News-Medical. August 24, 2020.
Chicago
Laguipus, Angela. “COVID-19 antihypertensive survival rates”. News-Medical. https://www.news-medical.net/news/20200824/Antihypertensives–COVID-19-survival-rates.aspx. (accessed 24 August 2020).
Harvard
Laguipus, Angela. 2020. Survival rates of antihypertensives in COVID-19. News-Medical, retrieved August 24, 2020, https://www.news-medical.net/news/20200824/Antihypertensives–COVID-19-survival-rates.aspx.
News-Medical.net – An AZoNetwork site
Ownership and operation through AZoNetwork, © 2000-2020